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Abstract
Endoplasmic Reticulum (ER)-associated degradation (ERAD) discards abnormal proteins synthesized in the ER. Through
coordinated actions of ERAD components, misfolded/anomalous proteins are recognized, ubiquitinated, extracted from the
ER and ultimately delivered to the proteasome for degradation. It is not well understood how ubiquitination of ERAD
substrates is regulated. Here, we present evidence that the deubiquitinating enzyme Ubiquitin-Specific Protease 25 (USP25)
is involved in ERAD. Our data support a model where USP25 counteracts ubiquitination of ERAD substrates by the ubiquitin
ligase HRD1, rescuing them from degradation by the proteasome.
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Introduction
Protein quality control consists of basic cellular pathways
necessary for homeostasis. Malfunctions in protein quality control
are linked to malignancies, neurodegenerative diseases and
metabolic syndromes [1]. In eukaryotic protein quality control
most short-lived, abnormal proteins are recycled by the ubiquitin-
proteasome system: proteins that need to be discarded are
selectively ubiquitinated and the poly-ubiquitin chain is ultimately
recognized by the proteasome for degradation. Post-translational
modification of proteins by ubiquitin is accomplished through the
concerted action of three enzymes. The ubiquitin-activating
enzyme (E1) activates ubiquitin and transfers it to a ubiquitin-
conjugating enzyme (E2). In the presence of a ubiquitin ligase (E3),
ubiquitin is transferred most commonly to a lysine residue of a
substrate protein. Like many other types of post-translational
modifications, ubiquitination is reversible. Indeed, deubiquitina-
tion is critical for normal cell function and is accomplished by
deubiquitinating enzymes (DUBs) [2,3]. The human genome
encodes nearly 90 DUBs [4], several of which have been linked to
protein quality control [2,3,5].
One function of the ubiquitin-proteasome system is to degrade
luminal or trans-membrane peptides that are produced in the
endoplasmic reticulum (ER) [1,6]. During ER-Associated Degra-
dation (ERAD), misfolded proteins are recognized, deglycosylated,
ubiquitinated, extracted into the cytosol and ultimately presented
to the proteasome for degradation [6]. Each step is conducted by
protein complexes that are recruited and assembled around
proteins that need to be degraded. HRD1 is one of several ER-
resident ubiquitin ligases involved in ubiquitination [7–9].
Ubiquitination of ERAD substrates is coupled to their extraction
from the ER into the cytosol by the AAA ATPase VCP/p97.
Substrate ubiquitination appears necessary for extraction [6].
VCP/p97 is brought to the ER membrane by cofactors that
recognize ubiquitin chains on ERAD substrates [1,6]. Following
extraction, substrates are escorted to the proteasome for degrada-
tion. Despite significant advances in understanding individual
steps in ERAD [1,6,10–13] and evidence of at least three DUBs
involved in this pathway (USP19, ataxin-3 and YOD1 [14–17]) it
is not entirely clear how substrate ubiquitination is regulated
during ERAD.
Ubiquitin-Specific Protease 25 (USP25) is a catalytically active
DUB in vitro [18,19], previously reported to regulate proteasomal
turnover of muscle proteins [18]. Here, we present evidence that
USP25 functions in ERAD. USP25 interacts with HRD1 and
VCP/p97 and rescues several ERAD substrates from degradation
by the proteasome. Our work sheds light on a previously unknown
ERAD component.
Results
USP25 localizes at the ER and interacts with ERAD
components
The two isoforms of the deubiquitinating enzyme USP25
(Figure 1A), according to a previous report, have a cellular
distribution somewhat reminiscent of ER staining [20]. Therefore,
we conducted confocal microscopy with an endogenous ER
marker. As shown in figure 1B, some USP25 localizes at the ER.
We consequently examined whether USP25 interacts with ERAD
components. By conducting co-immunoprecipitation experiments
from cells, we found that exogenous USP25 interacts with the ER-
resident ubiquitin ligase HRD1 and with endogenous VCP/p97
(Figure 1C). Conversely, HRD1 interacts with USP25 and VCP/
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interact in cells (Figure 1E), but USP25 does not interact with
other ubiquitin ligases implicated in ERAD [6,21–24]: UFD2/
E4B (Figure 1F) and GP78/AMFR (Figure 1G). These results
collectively demonstrate that USP25 interacts with some but not
all ERAD components, suggesting a specific or selective interac-
tion.
USP25 regulates turnover of several ERAD substrates
Since USP25 localizes at the ER and interacts with at least two
ERAD components (Figure 1), we tested whether USP25 regulates
protein levels of ERAD substrates. Both the common and muscle-
specific isoforms of USP25 lead to higher steady state protein levels
of the ERAD substrate CD3d (Figure 2A, left panel). CD3d is a
trans-membrane subunit of the T cell receptor that in the absence
of other subunits is degraded by the proteasome. USP25 seems to
rescue CD3d from proteasomal degradation, because after
treatment with the proteasome inhibitor MG132 the effect of
USP25 expression in stabilizing CD3d protein is no longer
observed (Figure 2A, right panel).
The catalytic activity of USP25 is necessary for its ability to
increase steady state levels of CD3d protein, as demonstrated by
using a USP25 construct, C178S, where the catalytic cysteine is
mutated into a serine residue (Figures 2B, 2C). Also, deleting either
the ubiquitin-associated domain (UBA) or the ubiquitin-interact-
ing motifs (UIMs) of USP25 abolishes the positive effect that
USP25 has on the steady state levels of CD3d protein (Figure 2B).
Thus, the ability of USP25 to both bind and cleave ubiquitin
appears to be required to exert the rescue effect on CD3d.
To examine the effect of USP25 in the turnover of CD3d
protein, we co-transfected cells with CD3d and either empty
vector, wild type USP25 or catalytically inactive USP25 (C178S),
then inhibited the translation of new protein with cycloheximide
for pre-determined periods of time. As shown in figure 2C, USP25
significantly decelerates the degradation of CD3d protein,
increasing its half-life. This effect depends on the catalytic activity
of USP25, as catalytically inactive USP25 (C178S) does not alter
the turnover of CD3d protein (Figure 2C). The cycloheximide-
based approach we used here is based on semi-quantification of
western blots. Although non-linear, this assay provides valuable
clues on the half-life and rates of protein turnover, supporting the
notion that catalytically active USP25 slows down the degradation
of CD3d protein.
Next, we examined whether USP25 and CD3d interact in cells.
Panels 2D and E show that USP25 and CD3d co-immunopre-
cipitate each other from cells. CD3d also co-immunoprecipitates
endogenous HRD1 alongside USP25 (Figure 2E), suggesting that
HRD1 and USP25 might co-regulate CD3d, forming part of the
same regulatory post-translational modification complex.
Another ERAD substrate is b-Amyloid Precursor Protein (APP),
whose turnover is reportedly regulated by HRD1 [25]. Catalyt-
ically active isoforms of USP25 lead to moderately, but statistically
significantly, higher steady state levels of APP protein in cells
(Figure 3A) similar to this DUB’s effect on the protein levels of
CD3d. The positive effect of USP25 on APP protein is detectable
only when the proteasome is active; treatment of transfected cells
with the inhibitor MG132 abolishes this effect (Figure 3A),
suggesting that USP25 rescues APP from proteasomal degrada-
tion. In cycloheximide-based time course experiments, where
production of new protein is halted, USP25 modestly, but
statistically significantly, slows down APP turnover (Figure 3B).
Similarly to what occurs with CD3d, overexpression of USP25
increases APP half-life. Again, this effect depends on the catalytic
activity of USP25, as catalytically inactive USP25(C178S) does not
alter APP turnover (Figure 3B).
On a side note, when comparing untreated cells to ones treated
with proteasome inhibitor, the muscle-specific isoform of USP25
(USP25(m)) appears less stable than its common counterpart
(USP25(WT)) in some cases (Figure 2A), but not so much in others
(Figure 3A). The basis of this difference is unclear. Perhaps the
stability of the USP25(m) isoform depends in part on its co-
expressed partners.
Since HEK-293 cells express APP endogenously, we ap-
proached the rescue effect of USP25 upon APP protein under
more physiological conditions, without over-expression of USP25.
We tested whether RNAi-mediated knockdown of endogenous
USP25 causes a reduction in endogenous APP protein levels. We
used 48- and 72-hour long transfection periods and tested seven
different shRNA constructs, but achieved only approximately 50%
reduction in endogenous USP25 protein (Figure 3C and data not
shown; see Materials and Methods). Still, even modest knockdown
of endogenous USP25 leads to significantly lower steady state
levels of endogenous APP protein (Figure 3C). Since APP and
USP25 also co-immunoprecipitate from cells (Figure 3D), our
results collectively suggest that USP25 regulates APP protein
degradation.
Although our data relate USP25 to ERAD substrate turnover
(Figures 1–3), we nevertheless wanted to address the possibility
that USP25 acts non-specifically on all proteasomal targets,
including both ERAD non-ERAD substrates. We examined the
effect of USP25 on steady state levels of yet another ERAD
substrate, CFTRDF508 [6], and two non-ERAD substrates, Ub-
R-GFP (N-End rule degradation; [26]) and GFP-ODC (proteaso-
mal degradation independent of a poly-ubiquitin signal; [27]).
USP25 increases the steady state protein levels of the ERAD
substrate CFTRDF508 (Figure 3E), but does not affect either non-
ERAD substrate (Figure 3F). Previous work also found that USP25
does not have a general effect on proteasomal targets, as assessed
by general ubiquitination patterns in cells [20]. Therefore, our
findings implicate USP25 more specifically in ERAD substrate
turnover, at least for some ERAD substrates.
USP25 opposes the effect of HRD1 on CD3d in cells
CD3d interacts with both USP25 and HRD1 in cells (Figure 2E),
suggesting a functional interaction between HRD1 and USP25 in
ERAD. Therefore, we examined the combinatorial effect of
HRD1 and USP25 on steady state levels of CD3d protein through
co-transfection experiments. HRD1 decreases steady state protein
levels of CD3d in a manner dependent on its catalytic activity
(lanes 1, 3 and 4 in Figure 4A), as reported previously [7]. The
positive effect of HRD1 on CD3d degradation is reversed by wild
type USP25, whose co-expression causes an increase in CD3d
protein levels (compare lanes 3 and 5 in Figure 4A). These data
support a model where USP25 counteracts the ubiquitin ligase
function of HRD1. Consequently, we investigated the effect of
HRD1 and USP25 on CD3d ubiquitination and its presumed
targeting to the proteasome for degradation, by using established,
stringent purification protocols to isolate CD3d from cells ([28–
31]; see Materials and Methods). As shown in figure 4B, HRD1
increases ubiquitination of CD3d in cells. The presence of USP25
significantly reduces levels of ubiquitinated CD3d (Figure 4B, C).
Notably, over-expression of catalytically inactive USP25(C178S)
does not have a noticeable effect on CD3d protein levels, its rate of
degradation or ubiquitination (Figure 2 and Figure 4C). These
results together with the interaction between CD3d and USP25
(Figure 2), suggest that USP25 might rescue CD3d from
proteasomal degradation by directly deubiquitinating it.
USP25 Functions in ER-Associated Degradation
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36542Figure 1. USP25 interacts with ERAD components. A) Schematics depict known domains of common (USP25(WT)) and muscle-specific
(USP25(m)) isoforms of USP25 that are expressed in mammals [18,19,41,42]. B) HEK-293 cells were transfected with HA-USP25. 48 hours later cells
were fixed, probed as indicated and imaged with laser confocal microscopy. Panels IA-IC are single optical plane images (1 mM) of a cell
immunolabeled for ER (KDEL, endogenous marker), HA-USP25 and nucleus (DAPI). Panel IC is the merged view of panels IA (green channel), IB (red
channel) and DAPI (blue channel; not shown as a separate channel). Panels II and III are merged views of other cells stained similarly to panel I. Scale
bars: 10 mM. C–G) HEK-293 cells were transfected as shown. Indicated constructs were immunopurified with bead-bound antibodies. Similar results
were obtained from COS-7 cells for panels B–E (not shown). All USP25 constructs used in this figure were the common isoform (USP25(WT)).
doi:10.1371/journal.pone.0036542.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36542Figure 2. USP25 inhibits degradation of the ERAD substrate CD3d. A) Western blots of whole cell lysates. Top: HEK-293 cells were transfected
as indicated and treated with the proteasome inhibitor MG132 where noted (15 mM, 6 hours) before harvesting. Bottom: semi-quantification of
bands from western blots shown above and other similar, independent experiments. CD3d protein levels were normalized to loading control. Shown
are means +/2 standard deviations. USP25(WT): common isoform of USP25; USP25(m): muscle-specific isoform of USP25. P values from Student T-
tests are shown below histograms. B) Top: HEK-293 cells were transfected with the indicated constructs and harvested 48 hours later. Shown are
western blots of whole cell lysates probed with the indicated antibodies. WT: wild type USP25, C178S: the catalytic cysteine of USP25 was replaced by
a serine residue [18], DUBA: UBA deleted, DUIM: both UIMs deleted. Bottom: semi-quantification of data from the top and two other independent
experiments. CD3d protein levels were normalized to loading control. Shown are means +/2 standard deviations. P values from Student T-tests are
shown below histograms. C) Top: HEK-293 cells were transfected as indicated. 48 hours post-transfection cells were treated for the indicated periods
of time with 75 mg/ml cycloheximide to inhibit synthesis of new protein. Bottom: semi-quantification of western blots from the top and three other,
independent experiments. CD3d levels were normalized to loading control. Shown are means +/2 standard deviations. P values are from Student T-
tests of USP25 compared to vector control. D and E) HEK-293 cells were transfected with the indicated constructs. 48 hours later tagged constructs
were immunopurified with bead-bound antibodies and probed as indicated.
doi:10.1371/journal.pone.0036542.g002
Figure 3. USP25 regulates protein levels of the ERAD substrates APP and CFTRDF508. A) Left: whole cell lysates of HEK-293 cells
transfected with the indicated constructs. USP25 (WT) and USP25(m) are both catalytically active isoforms. Where noted, cells were treated with the
proteasome inhibitor MG132 (15 mM, 6 hrs) before harvesting. Right: histograms show semi-quantification of APP signal from the left portion and
other similar, independent experiments. Bracket: APP bands were quantified separately, added and normalized to loading control. Shown are means
+/2 standard deviations. P values from Student T-tests are shown above histograms. No statistically significant differences were observed when cells
were treated with MG132. B) Left: whole cells lysates of HEK-293 cells transfected as indicated and treated 48 hours later with cycloheximide to
inhibit translation of new protein. Right: semi-quantification of western blots from the right and two other independent experiments. Shown are
means +/2 standard deviations. APP levels were normalized to loading control. P values are from Student T-tests where APP levels in the presence of
USP25(WT) were compared to APP levels in presence of vector control. C) Left: HEK-293 cells were transfected with shRNA constructs targeting
different portions of endogenous USP25 (RNAi-1, 2) or scramble RNA (RNAscr-1, 2). Cells were harvested 48 hours post-transfection and probed as
indicated in western blots. Trials with 72 hour-long transfections yielded similar results (not shown). Right: semi-quantification of signal from the left
and other similar, independent experiments. Bracket: APP bands were quantified separately, added together and normalized to loading control.
Asterisks: P,0.01 according to Student T-tests comparing RNAi-1 and RNAi-2 lanes to RNAi-scr lanes. D) HEK-293 cells were transfected with the
indicated constructs and Myc-USP25 was co-immunoprecipitated 48 hours later. E and F) HEK-293 cells were transfected with the indicated
constructs. Western blots of whole cell lysates. For panels D, E and F: similar results were obtained from COS-7 cells (not shown).
doi:10.1371/journal.pone.0036542.g003
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associated with HRD1 and VCP/p97
We next examined the effect of USP25 on the ubiquitination
status of endogenous proteins associated with HRD1 and their
presumptive targeting to the proteasome. We immunopurified
endogenous proteins associated with transfected HRD1 from cells
in the absence or presence of co-transfected USP25, following
previously published protocols ([16,17]; see Materials and
Methods). As shown in figure 5A, USP25 significantly reduces
levels of endogenous ubiquitinated species that co-immunoprecip-
itate with HRD1. Importantly, the effect of USP25 on lowering
levels of ubiquitinated species that co-immunoprecipiate with
HRD1 depends on the catalytic activity and ubiquitin-binding
domains of USP25: neither catalytically inactive USP25(C178S)
(Figure 5A) nor USP25 with deleted UBA or UIMs (Figure 5B)
have the same effect. These results further suggest that USP25
counteracts the ubiquitin ligase function of HRD1 by binding
ubiquitinated species and cleaving them. Lastly, neither the UBA
nor the UIMs of USP25 appear important for its ability to interact
with HRD1, since HRD1 interacts with USP25 lacking either
domain (Figure 5B).
Because USP25 also interacts with endogenous VCP/p97
(Figure 1), we investigated the effect of USP25 on the ubiquitina-
tion status of endogenous proteins associated with VCP/p97. As
shown in figure 5C, transfected USP25 reduces ubiquitination of
endogenous species associated with transfected and endogenous
VCP/p97. However, the effect of USP25 on VCP/p97 ubiqui-
tinated clients is not as statistically robust as that on HRD1-
associated species. Collectively, this work suggests that USP25 has
a general inhibitory effect on ERAD substrate turnover, partic-
ularly on HRD1 substrates.
Discussion
Regulation of ubiquitin-dependent mechanisms in ERAD is not
fully understood. Here, we presented evidence that the DUB
USP25 is a component of ERAD. USP25 joins other DUBs
involved in ERAD: ataxin-3 [16,17], YOD1 [14] and USP19 [15].
USP19 is a trans-membrane DUB on the cytoplasmic face of the
ER membrane, where it reportedly rescues ERAD substrates
through deubiquitination [15]. It is unclear with which ERAD
components USP19 interacts functionally. Ataxin-3 and YOD1
are involved in ERAD by binding directly to VCP/p97. Their
DUB activity appears to mediate delivery of ERAD substrates to
the proteasome by VCP/p97 [14,16,17].
According to our results, USP25: a) interacted with and rescued
the ERAD substrates CD3d and APP, and counteracted HRD1
Figure 4. USP25 and HRD1 have opposing effects on CD3d protein levels and ubiquitination. A) HEK-293 cells were transfected as
indicated and harvested 48 hours later. Western blots are from whole cell lysates. HRD1(WT): normal HRD1; HRD1(CA): catalytically inactive HRD1, in
which the catalytic cysteine is substituted by an alanine residue [7]. Histograms on the right: semi-quantification of data from the left and other
independent experiments. Shown are means +/2 standard deviations. CD3d levels were normalized to loading control. P values from Student T tests
are shown below histograms. B and C) HEK-293 cells were transfected with the indicated constructs. 48 hours post transfection, cells were treated for
6 hours with MG132 (15 mM) and HA-CD3d was immunopurified using bead-bound anti-HA antibody after a stringent denature/renature step (see
Materials and Methods for details). Histograms: semi-quantification of bracketed ubiquitin smears from the experiment on the left and other similar,
independent experiments. Shown are means +/2 standard deviations. P values for panel C are from Student T-tests.
doi:10.1371/journal.pone.0036542.g004
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the ERAD components HRD1 and VCP/p97, c) reduced the
levels of endogenous ubiquitinated species associated with HRD1
and VCP/p97, and d) regulated the levels of endogenous APP, as
knockdown of endogenous USP25 was associated with lower levels
of endogenous APP. Based on these data, we propose that USP25
deubiquitinates ERAD substrates while or after they are
ubiquitinated by HRD1, rescuing them from proteasomal
degradation. The catalytic activity and ubiquitin-binding domains
of USP25 appear necessary both to rescue ERAD substrates and
to lower the levels of HRD1-associated ubiquitinated species,
suggesting that USP25 must bind ubiquitin chains in order to
cleave them. According to previous reports, CFTRDF508 is not an
HRD1 substrate [6]. Therefore, our results where USP25
increased CFTRDF508 protein levels suggest that USP25 could
also function in ERAD independently of HRD1. However, we did
not observe an interaction between USP25 and other ligases
implicated in ERAD, GP78/AMFR and UFD2/E4B.
Our model of USP25 action differs from that of YOD1 and
ataxin-3. Through direct interactions with VCP/p97, ataxin-3 and
YOD1 function after VCP/p97 is recruited to the ER membrane
[14,16,17]. Once VCP/p97 is recruited to the ER membrane by
ubiquitinated substrates, deubiquitination seems necessary for
their extraction by VCP/p97 [6]. For example, catalytically
inactive YOD1 leads to accumulation of ERAD substrates at a
step preceding VCP/p97-dependent extraction [14,32]. After
successful extraction, substrates are presumably re-ubiquitinated
by cytosolic ubiquitin ligases and finally escorted to the protea-
some for degradation [6]. Since USP25 interacted with VCP/p97,
USP25 might deubiquitinate ERAD substrates while they are
bound by VCP/p97. However, if USP25 were to deubiquitinate
substrates bound by VCP/p97, it would be expected to facilitate
substrate extraction from the ER and enhance their subsequent
degradation [14,32]. Instead, we observed that USP25 rescued
ERAD substrates and reduced levels of ubiquitination of HRD1-
associated species. Our work suggests that USP25 functions during
substrate ubiquitination at the ER membrane, before extraction by
VCP/p97. Data in figure 5C, where lower levels of ubiquitinated
species associated with VCP/p97 in the presence of USP25 were
observed, could be due to fewer ERAD substrates available for
recognition and extraction by VCP/p97.
It is unclear whether USP25-HRD1 or USP25-VCP/p97
interactions are direct. Sequence analyses did not identify areas
indicative of a direct interaction between USP25 and VCP/p97
(not shown). Mammalian HRD1 does interact directly with VCP/
p97 [33], which can explain our observation that USP25 co-
precipitated VCP/p97. It needs to be determined how the
Figure 5. USP25 reduces levels of ubiquitinated endogenous proteins associated with HRD1 or VCP/p97. A–C) HEK-293 cells were
transfected as indicated. 48 hours later cells were harvested and constructs were immunopurified with bead-bound anti-V5 antibody to isolate V5-
HRD1-associated protein (panels A and B), or with bead-bound anti-GFP antibody to isolate GFP-VCP-associated proteins (panel C). We did not detect
ubiquitin species in western blots from stringent, denature/renature immunoprecipitations of HRD1 or VCP/p97 using RIPA buffer (data not shown),
indicating that the ubiquitin signal we observe in this figure is due to species associated with HRD1 or VCP/p97. Shown are western blots of inputs
from whole cells lysates and from immunopurified protein. Histograms are semi-quantifications of results from the left and other similar, independent
experiments. Shown are means +/2 standard deviations. P values for panels A and C are from Student-T tests.
doi:10.1371/journal.pone.0036542.g005
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other components is precisely coordinated during ERAD.
E3 ligases and DUBs interact functionally to decide the fate of a
protein [34–37]. The interaction between USP25 and HRD1
could serve as an editing step to help determine whether a protein
should undergo ERAD. Functional interactions between DUBs
(e.g. USP25) and ubiquitin ligases (e.g. HRD1) are probably
dynamically monitored to ensure optimal recycling rates for either
specific proteins or in-bulk degradation during protein quality
control.
According to our results, USP25 altered the levels of APP. This
finding may have implications for Alzheimer’s Disease, because
mutated forms of APP and higher levels of wild type APP are
linked to Alzheimer’s Disease [38]. Our observations that USP25
interacted with APP and affected APP turnover implicate USP25
in Alzheimer’s Disease pathogenesis and may serve as a point of
intervention for new therapeutic strategies. Future studies are
necessary to understand the precise molecular mechanism of
USP25 function in ERAD, as well as its potential implication in




All constructs have been previously described
[7,17,18,26,27,39,40]. For RNAi-mediated knockdown, two
scrambled negative controls and seven USP25 shRNA constructs
(V2LHS_63867, V2LHS_63830, V2LHS_63903, V2LHS_63904,
V2LHS_63902, V2LHS_5201, V3LHS_310311) were purchased
from Open Biosystems. Antibodies: mouse anti-APP, clone 22c11
from Millipore, was used at 1:1000 dilution; mouse anti-Myc,
clone 9e10 from Santa Cruz Biotech, was used at 1:250 dilution;
rabbit anti-HA, clone Y11 from Santa Cruz Biotech, was used at
1:1000 dilution; mouse anti-V5 from Invitrogen, was used at
1:5000 dilution; rabbit anti-ubiquitin from Dako, was used at
1:500 dilution; rabbit anti-GFP from Santa Cruz Biotech, was
used at 1:1000 dilution; rabbit anti-VCP from Millipore, was used
at 1:5000 dilution; mouse anti-KDEL from Enzo Life Sciences,
was used at 1:500 dilution; rabbit anti-USP25 was described
previously [18,20], and was used at 1:4000 dilution; mouse anti-
E4B from BD Biosciences, was used at 1:500 dilution; rabbit anti-
GP78/AMFR from Cell Signaling, was used at 1:1000 dilution;
mouse anti-Tubulin from Sigma-Aldrich, was used at 1:40000
dilution. Peroxidase-conjugated, secondary antibodies were from
Jackson Immunoresearch, were used at 1:15000 dilution.
Cell transfections, imaging, densitometry and
immunofluorescence
HEK-293 and COS-7 cell lines used in this study were
purchased from ATCC and grown using standard conditions.
Cells were transfected using Lipofectamine LTX (Invitrogen),
following the manufacturer’s instructions. 48 hours post-transfec-
tion, cells were harvested in 1% SDS/100mM DTT boiling lysis
buffer for whole cell extracts. For RNAi-mediated knockdown, 72-
hour transfections were also conducted, with similar results.
Western blotting, digital imaging and densitometry were conduct-
ed as previously described [30,31] using a CCD camera-equipped
Bio-Rad Versadoc 5000MP imager. Images were all collected
below saturation levels and background was removed uniformly
before semi-quantification with Quantity One software (Bio-Rad).
For pulse chase-analysis, 48 hours post-transfection cells were
treated with 75 mg/ml cycloheximide (AG Scientific) freshly
dissolved in water, or with the vehicle control for 0–6 hours, at
which time cells were harvested in boiling SDS/DTT lysis buffer
and electrophoresed for western blots. MG132 was purchased
from Boston Biochem, dissolved in DMSO and used at [15 mM]
final concentration. Statistical analyses were performed using the
Student T-test. Immunofluorescence was conducted as previously
described [29]. All images were taken with a 100X oil-immersion
lens.
Immunopurifications
Immunopurifications were conducted as previously described
[29–31]. Briefly: for co-immunopurification, cells pelleted in ice-
cold PBS were lysed in NETN lysis buffer ([50 mM] TRIS-
pH 7.5, [150 mM] NaCl, 0.5% NP40) supplemented with
protease inhibitor (PI) tablets (Sigma-Aldrich) and tagged protein
was precipitated using anti-tag, bead-bound antibodies (Sigma-
Aldrich). Beads were washed 3X with NETN+PI and protein was
eluted from beads with 2% SDS.
For stringent, denature-renature immunopurification, cells were
lysed in RIPA buffer ([50 mM] Tris, [150 mM] NaCl, 0.1% SDS,
0.5% deoxycholic-acid, 1% NP40, pH 7.4) + PI, denatured in 1%
final concentration SDS for 30 minutes at room temperature and
then renatured in 4.5% final concentration TritonX-100 for
30 minutes. Protein immunopurified with bead-bound antibodies
(Sigma-Aldrich) was rinsed extensively with RIPA+PI (5X–8X)
and eluted with 2% SDS.
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